(Q48546499)

12 February 2018

title

A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme (English)

1 reference

12 February 2018

1 reference

Miller D

1

1 reference

12 February 2018

Bennett L

2

1 reference

12 February 2018

Hollis K

3

1 reference

12 February 2018

Tennis P

4

1 reference

12 February 2018

Cook S

5

1 reference

12 February 2018

Andrews E

6

1 reference

12 February 2018

language of work or name

English

0 references

publication date

1 September 2006

1 reference

12 February 2018

Alimentary Pharmacology & Therapeutics

published in

1 reference

12 February 2018

volume

24

1 reference

12 February 2018

issue

5

1 reference

12 February 2018

page(s)

869-878

1 reference

12 February 2018

A national survey of practice patterns of gastroenterologists with comparison to the past two decades

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

The treatment of irritable bowel syndrome with hypnotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Treatment options in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Update in the therapeutic management of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Practitioner acceptance of the dofetilide risk-management program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

Post-marketing surveillance using pharmacy-based cohorts: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03031.X

10.1111/J.1365-2036.2006.03031.X

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018